You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
億帆醫藥(002019.SZ):2023年度預虧3.82億元–6.50億元
格隆匯 01-30 23:05

格隆匯1月30日丨億帆醫藥(002019.SZ)公佈2023年度業績預吿,報吿期歸屬於上市公司股東的淨利潤虧損38,200萬元–65,000萬元,上年同期盈利19,127.74萬元;扣除非經常性損益後的淨利潤虧損37,100萬元–63,900萬元,上年同期盈利7,937.13萬元;基本每股收益虧損0.31元/股–0.53元/股。

公司根據《企業會計準則第8號-資產減值》的規定對長期資產的減值跡象進行判斷,並進行了減值測試。其中公司控股子公司EviveBiotechLtd.(億一生物)自主研發的無形資產F-627(艾貝格司亭α注射液)合併報表期末原值為168,438萬元,擬計提減值準備80,000.00萬元—88,000.00萬元,預計減少歸屬於上市公司股東淨利潤48,600.00萬元—54,700.00萬元。2023年F-627先後在中國、美國成功獲批,但全球市場競爭格局與競爭態勢發生重大變化(競品數量增加及競品價格下降),呈現不利影響,預計未來可收回金額不及預期導致減值,最終減值金額將由公司聘請的評估機構、會計師事務所進行評估和審計後確定。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account